REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Clinical trials for REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE trials appear
Sign up with your email to follow new studies for REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo may reduce transplant complications in blood cancer patients
Disease control CompletedThis study tested different combinations of immune-suppressing drugs to prevent graft-versus-host disease (GVHD) in 174 patients with blood cancers who received a stem cell transplant from an unrelated donor. The goal was to find the most effective approach to reduce severe GVHD,…
Matched conditions: REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New drug flotetuzumab tested for tough blood cancers
Disease control CompletedThis early-stage trial tested the safety and best dose of flotetuzumab, a lab-made antibody, in 13 people with advanced blood cancers that had come back or stopped responding to treatment. The goal was to see if the drug could help control the disease by blocking cancer cell grow…
Matched conditions: REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 04, 2026 16:18 UTC